Literature DB >> 30729271

Demethylzeylasteral (T-96) inhibits triple-negative breast cancer invasion by blocking the canonical and non-canonical TGF-β signaling pathways.

Liu Li1, Yi Ji1, Junting Fan2, Furong Li3, Yan Li3, Mianhua Wu4,5, Haibo Cheng6,7, Changliang Xu8,9.   

Abstract

Inflammation is one of the characteristic features during the development of human tumors. A pro-inflammatory cytokine that is known to promote inflammation during cancer development is the transforming growth factor-β (TGF-β). On the other hand, demethylzeylasteral (T-96) is a natural compound isolated from Tripterygium wilfordii Hook F, which has been reported to have various pharmacological properties including anti-inflammatory and immunosuppressive activities. We investigated the effects of T-96 on the highly metastatic breast cancer cell line, MDA-MB-231. Cell migration was assessed by scratch-wound migration assay, and the molecular mechanisms underlying the effects of T-96 were examined by qPCR and Western blot analyses. We also investigated the suppression effects of T-96 on the pulmonary metastasis in the 4T1 mouse model. T-96 inhibited TGF-β-induced migration and epithelial-mesenchymal transition both in vitro and in vivo. These results demonstrate that T-96 inhibited invasion of MDA-MB-231 and 4T1 cells via suppressing the canonical and non-canonical TGF-β signaling pathways.

Entities:  

Keywords:  Breast cancer; Invasion; T-96; TGF-β

Mesh:

Substances:

Year:  2019        PMID: 30729271     DOI: 10.1007/s00210-019-01614-5

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  49 in total

Review 1.  Triple-negative breast cancer.

Authors:  William D Foulkes; Ian E Smith; Jorge S Reis-Filho
Journal:  N Engl J Med       Date:  2010-11-11       Impact factor: 91.245

2.  MiR-200c suppresses TGF-β signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer.

Authors:  Wen-Dong Bai; Xing-Ming Ye; Meng-Yao Zhang; Hua-Yu Zhu; Wen-Jin Xi; Xun Huang; Jiao Zhao; Bin Gu; Guo-Xu Zheng; An-Gang Yang; Lin-Tao Jia
Journal:  Int J Cancer       Date:  2014-03-03       Impact factor: 7.396

3.  TGFbeta regulation of mitogen-activated protein kinases in human breast cancer cells.

Authors:  R S Frey; K M Mulder
Journal:  Cancer Lett       Date:  1997-07-15       Impact factor: 8.679

Review 4.  Targeting EMT in cancer: opportunities for pharmacological intervention.

Authors:  Felicity M Davis; Teneale A Stewart; Erik W Thompson; Gregory R Monteith
Journal:  Trends Pharmacol Sci       Date:  2014-07-16       Impact factor: 14.819

Review 5.  TGF-β signalling and its role in cancer progression and metastasis.

Authors:  Yvette Drabsch; Peter ten Dijke
Journal:  Cancer Metastasis Rev       Date:  2012-12       Impact factor: 9.264

6.  Effects of demethylzeylasteral and celastrol on spermatogenic cell Ca2+ channels and progesterone-induced sperm acrosome reaction.

Authors:  Jun-Ping Bai; Yu-Liang Shi; Xin Fang; Qi-Xian Shi
Journal:  Eur J Pharmacol       Date:  2003-03-07       Impact factor: 4.432

7.  ERK1/2 blockade prevents epithelial-mesenchymal transition in lung cancer cells and promotes their sensitivity to EGFR inhibition.

Authors:  Janine M Buonato; Matthew J Lazzara
Journal:  Cancer Res       Date:  2013-10-09       Impact factor: 12.701

8.  TNF-alpha suppresses alpha-smooth muscle actin expression in human dermal fibroblasts: an implication for abnormal wound healing.

Authors:  Mytien T Goldberg; Yuan-Ping Han; Chunli Yan; Michael C Shaw; Warren L Garner
Journal:  J Invest Dermatol       Date:  2007-05-31       Impact factor: 8.551

9.  TGF-β1 modulates the homeostasis between MMPs and MMP inhibitors through p38 MAPK and ERK1/2 in highly invasive breast cancer cells.

Authors:  Luciana R Gomes; Letícia F Terra; Rosângela Am Wailemann; Leticia Labriola; Mari C Sogayar
Journal:  BMC Cancer       Date:  2012-01-19       Impact factor: 4.430

10.  ELF5 Drives Lung Metastasis in Luminal Breast Cancer through Recruitment of Gr1+ CD11b+ Myeloid-Derived Suppressor Cells.

Authors:  David Gallego-Ortega; Anita Ledger; Daniel L Roden; Andrew M K Law; Astrid Magenau; Zoya Kikhtyak; Christina Cho; Stephanie L Allerdice; Heather J Lee; Fatima Valdes-Mora; David Herrmann; Robert Salomon; Adelaide I J Young; Brian Y Lee; C Marcelo Sergio; Warren Kaplan; Catherine Piggin; James R W Conway; Brian Rabinovich; Ewan K A Millar; Samantha R Oakes; Tatyana Chtanova; Alexander Swarbrick; Matthew J Naylor; Sandra O'Toole; Andrew R Green; Paul Timpson; Julia M W Gee; Ian O Ellis; Susan J Clark; Christopher J Ormandy
Journal:  PLoS Biol       Date:  2015-12-30       Impact factor: 8.029

View more
  4 in total

1.  Identification of an antitumor effect of demethylzeylasteral on human gastric cancer cells.

Authors:  Yang Yang; Menglin Zhao; Ting Hu; Fang Su; Feng Qian; Zishu Wang
Journal:  Oncol Lett       Date:  2020-11-18       Impact factor: 2.967

2.  Demethylzeylasteral inhibits proliferation, migration, and invasion through FBXW7/c-Myc axis in gastric cancer.

Authors:  Yongsen Li; Yongyue Su; Yuzu Zhao; Xiaosong Hu; Gaichao Zhao; Jiang He; Sicheng Wan; Muhan Lü; Hongjuan Cui
Journal:  MedComm (2020)       Date:  2021-06-03

3.  Demethylzeylasteral reduces the level of proteinuria in diabetic nephropathy: Screening of network pharmacology and verification by animal experiment.

Authors:  Lengnan Xu; Ban Zhao; Liping Yang; Xinyi Dong; Xue Yang; Yonghui Mao
Journal:  Pharmacol Res Perspect       Date:  2022-08

4.  Demethylzelasteral inhibits proliferation and EMT via repressing Wnt/β-catenin signaling in esophageal squamous cell carcinoma.

Authors:  Jiarui Yu; Wei Wang; Baolin Liu; Jinling Gu; Siyuan Chen; Yishuang Cui; Guogui Sun
Journal:  J Cancer       Date:  2021-05-10       Impact factor: 4.207

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.